# 📊 CMO Agent Evaluation Report

**Test Suite:** Real World  
*Production-grade test cases derived from actual user queries and clinical scenarios*

The Real World test suite evaluates the CMO Agent's performance on queries taken from production usage, representing the complexity and nuance of actual medical questions. These tests validate the agent's ability to handle real clinical scenarios with appropriate medical reasoning, specialist selection, and comprehensive analysis.

**Date:** 2025-06-28T03:44:25  
**Evaluation Type:** Hybrid (Deterministic + LLM Judge)

---

## Executive Summary

### 🔴 CMO Agent Test Suite: **FAILED**
**Overall Score**: 94.0%
**Test Cases Evaluated**: 4

**Failure Reason**: One or more evaluation dimensions did not meet their minimum threshold requirements.
*Each test case is evaluated on 5 dimensions. The test suite fails if ANY dimension's average score across all tests falls below its target threshold.*

**Failed Dimensions**: 1 of 5
- Analysis Quality

### Test Case Summary
*Individual test results with dimension failures*

| Test Case | Status | Failed Dimensions | Complexity |
|-----------|--------|-------------------|------------|
| standard_001 | ✅ PASS | None | STANDARD |
| standard_002 | ❌ FAIL | Quality | STANDARD |
| complex_001 | ❌ FAIL | Quality | COMPLEX |
| complex_002 | ❌ FAIL | Quality | COMPLEX |
| **TOTAL** | **1/4 Passed** | **3 tests with failures** | - |

### Dimension Performance Across All Tests
*Average scores across all test cases for each evaluation dimension*

| Dimension | Score | Target | Status | Method | Description |
|-----------|-------|--------|--------|--------|-------------|
| Analysis Quality | 0.752 | 0.800 | ❌ FAIL | 🧠 LLM Judge | Comprehensiveness of medical analysis |
| Complexity Classification | 1.000 | 0.900 | ✅ PASS | 🔄 Hybrid | Accuracy of query complexity classification |
| Specialty Selection | 0.950 | 0.850 | ✅ PASS | 🧠 LLM Judge | Precision in selecting appropriate medical specialists |
| Tool Usage | 1.000 | 0.900 | ✅ PASS | 🔧 Deterministic | Effectiveness of tool calls |
| Response Structure | 1.000 | 0.950 | ✅ PASS | 🔧 Deterministic | Compliance with XML format |

**Dimension Failure Details:**
- **Analysis Quality**: 3 of 4 tests failed (75%)

## 🔍 Failure Patterns & Common Issues

### Analysis Quality Issues
Found 3 test(s) below quality threshold.
**Most common issue**: Comprehensive Approach (failed in 3 tests)

> 💡 **Note**: Detailed analysis for each test is available in the Test Results section below.

## Test Results Detail

**Prompts Being Tested:**
- [`1_initial_analysis.txt`](../../../services/agents/cmo/prompts/1_initial_analysis.txt) - Analyzes query complexity
- [`2_initial_analysis_summarize.txt`](../../../services/agents/cmo/prompts/2_initial_analysis_summarize.txt) - Summarizes findings
- [`3_task_creation.txt`](../../../services/agents/cmo/prompts/3_task_creation.txt) - Creates specialist tasks

### Test Case: standard_001 ✅

**Health Query:**  
What's my cholesterol trend over my entire data? I want to see trends across the top 4 cholesterol metrics including Triglycerides across that time period

**Response Time:** 56.1s

#### Evaluation Summary

| Dimension | Expected | Actual | Score | Target | Status |
|-----------|----------|--------|-------|--------|--------|
| **Complexity Classification** | STANDARD | STANDARD | 1.00 | 0.90 | ✅ PASS |
| **Specialist Selection** | cardiology, data_analysis, endocrinology | cardiology, data_analysis, endocrinology | 1.00 | 0.85 | ✅ PASS |
| **Analysis Quality** | ≥0.80 | 0.83 | 0.83 | 0.80 | ✅ PASS |
| **Tool Usage** | Effective | 1 calls | 1.00 | 0.90 | ✅ PASS |
| **Response Structure** | Valid XML | Valid | 1.00 | 0.95 | ✅ PASS |

#### Health Query Response/Analysis
<details>
<summary>View the agent's full medical approach</summary>

```
Detailed medical approach including:

**What specialists are needed and why:**
- **Primary Care Physician/Internist**: To oversee overall cardiovascular risk assessment and coordinate care
- **Cardiologist**: Given the significant fluctuations in triglycerides (ranging from 51 to 426 mg/dL) and periods of low HDL cholesterol, cardiovascular specialist input would be valuable for risk stratification

**Key data points to investigate:**
1. **Time span**: Data covers approximately 11 years (2013-2025)
2. **Critical trends identified**:
   - Total Cholesterol: Shows improvement from higher values (187 mg/dL in 2016) to more recent optimal levels (110-149 mg/dL in 2021-2025)
   - LDL Cholesterol: Generally well-controlled, ranging from 54-122 mg/dL
   - HDL Cholesterol: Concerning pattern of frequently low values, with multiple readings below 40 mg/dL (flagged as "OUT OF RANGE")
   - Triglycerides: Highly variable with concerning spikes (426 mg/dL in 2013, 390 mg/dL in 2014) and more recent moderate elevation (153 mg/dL in April 2025)

**Potential correlations to explore:**
- Relationship between triglyceride spikes and HDL suppression
- Impact of interventions between 2014-2021 that led to improved control
- Recent trend reversal in 2025 with increasing triglycerides

**Any immediate concerns noted:**
1. **Historically very high triglycerides** (>400 mg/dL) which pose pancreatitis risk
2. **Persistently low HDL cholesterol** (frequently <40 mg/dL), which is a significant cardiovascular risk factor
3. **Recent upward trend** in triglycerides (153 mg/dL in April 2025 vs 53-86 mg/dL in 2022-2023)
4. **Metabolic syndrome indicators**: The combination of high triglycerides and low HDL suggests possible metabolic dysfunction

This warrants a comprehensive trend analysis with visual representation to better understand the patterns and guide therapeutic decisions.
```
</details>


### Test Case: standard_002 ❌

**Health Query:**  
Show my abnormal lab results from labs this year?

**Response Time:** 53.7s

#### Evaluation Summary

| Dimension | Expected | Actual | Score | Target | Status |
|-----------|----------|--------|-------|--------|--------|
| **Complexity Classification** | STANDARD | STANDARD | 1.00 | 0.90 | ✅ PASS |
| **Specialist Selection** | endocrinology, laboratory_medicine, preventive_medicine | cardiology, endocrinology, laboratory_medicine | 0.90 | 0.85 | ✅ PASS |
| **Analysis Quality** | ≥0.80 | 0.68 | 0.68 | 0.80 | ❌ FAIL |
| **Tool Usage** | Effective | 1 calls | 1.00 | 0.90 | ✅ PASS |
| **Response Structure** | Valid XML | Valid | 1.00 | 0.95 | ✅ PASS |

#### 🔬 LLM Judge Failure Analysis

**Analysis Quality Issue:**
- **Problem**: The CMO's analysis focuses heavily on metabolic and kidney issues but fails to provide a comprehensive review of all abnormal lab results from the current year as requested
- **Root Cause**: The analysis fixated on specific abnormal values (HbA1c and BUN) without systematically addressing all abnormal results or providing a complete temporal analysis for the year
- **Priority**: HIGH
- **Weak Components**:
  - Comprehensive Approach: Failed to establish a systematic framework for reviewing all abnormal lab results, missing potential patterns across different lab categories and time periods throughout the year
- **Prompt to Update**: `backend/services/agents/cmo/prompts/1_initial_analysis.txt`
- **Recommended Prompt Changes**:
  - Add instruction in prompt: 'Create a comprehensive timeline of ALL abnormal lab results for the specified time period'
  - Add instruction in prompt: 'Categorize abnormal results by laboratory type (hematology, chemistry, immunology, etc.)'
  - Modify section in prompt: 'Include trend analysis for each abnormal result if multiple data points exist'
  - Add instruction in prompt: 'Compare each abnormal result against reference ranges and indicate degree of abnormality'
  - Add instruction in prompt: 'Review normal results that are trending toward abnormal ranges'
- **Expected Impact**: These improvements will ensure a complete review of all abnormal lab results, provide better temporal context, and identify patterns that might be clinically relevant across different laboratory categories

#### Health Query Response/Analysis
<details>
<summary>View the agent's full medical approach</summary>

```
Detailed medical approach including:

**Specialists Needed:**
1. **Internal Medicine/Primary Care** - For overall assessment and coordination of care
2. **Endocrinology** - Due to elevated HbA1c (6.1%) indicating prediabetes or early diabetes
3. **Nephrology consultation consideration** - Due to elevated Blood Urea Nitrogen (BUN) at 23 mg/dL

**Key Data Points to Investigate:**
1. **Metabolic Panel Trends:**
   - Need to examine complete metabolic panel including creatinine, eGFR, and electrolytes
   - BUN/Creatinine ratio to assess kidney function
   - Fasting glucose levels to correlate with HbA1c findings

2. **Diabetes Risk Assessment:**
   - HbA1c of 6.1% is in the prediabetic range (5.7-6.4%)
   - Need to review any previous HbA1c values for trend analysis
   - Check for other metabolic syndrome markers (lipid panel, blood pressure)

3. **Kidney Function Evaluation:**
   - Elevated BUN needs context with creatinine levels
   - Calculate eGFR if available
   - Review for proteinuria or other kidney function markers

**Potential Correlations to Explore:**
- Relationship between elevated BUN and HbA1c (early diabetic nephropathy risk)
- Hydration status affecting BUN levels
- Dietary protein intake influence on BUN
- Medication effects on both kidney function and glucose metabolism

**Immediate Concerns Noted:**
1. **Prediabetes/Early Diabetes:** HbA1c of 6.1% requires lifestyle intervention and monitoring
2. **Mild Kidney Function Concern:** BUN elevation needs further evaluation with complete renal panel
3. **Risk Stratification:** Patient needs cardiovascular risk assessment given metabolic abnormalities

**Next Steps:**
- Query for complete metabolic panel results
- Look for any previous HbA1c values for comparison
- Check for additional cardiovascular risk factors
- Review medications that might affect these values
```
</details>


### Test Case: complex_001 ❌

**Health Query:**  
Analyze cholesterol relevant medication adherence patterns over that time period and how do they correlate with these cholesterol lab results.

**Response Time:** 76.1s

#### Evaluation Summary

| Dimension | Expected | Actual | Score | Target | Status |
|-----------|----------|--------|-------|--------|--------|
| **Complexity Classification** | COMPLEX | COMPLEX | 1.00 | 0.90 | ✅ PASS |
| **Specialist Selection** | cardiology, data_analysis, endocrinology, laboratory_medicine, pharmacy | cardiology, data_analysis, endocrinology, laboratory_medicine, pharmacy | 1.00 | 0.85 | ✅ PASS |
| **Analysis Quality** | ≥0.80 | 0.75 | 0.75 | 0.80 | ❌ FAIL |
| **Tool Usage** | Effective | 1 calls | 1.00 | 0.90 | ✅ PASS |
| **Response Structure** | Valid XML | Valid | 1.00 | 0.95 | ✅ PASS |

#### 🔬 LLM Judge Failure Analysis

**Analysis Quality Issue:**
- **Problem**: The CMO's analysis lacks comprehensive integration of multiple factors affecting cholesterol management and fails to address several expected key data points
- **Root Cause**: The analysis focuses primarily on direct medication-lab correlations without considering broader patient context and lifestyle factors that influence cholesterol management
- **Priority**: HIGH
- **Weak Components**:
  - Comprehensive Approach: Missing analysis of lifestyle factors, comorbidities, diet, exercise patterns, and their impact on medication effectiveness and adherence. Also lacking discussion of social determinants of health that might affect adherence.
- **Prompt to Update**: `backend/services/agents/cmo/prompts/1_initial_analysis.txt`
- **Recommended Prompt Changes**:
  - Add instruction in prompt: 'Include analysis of lifestyle factors (diet, exercise, weight changes) and their correlation with medication adherence and lab results'
  - Add instruction in prompt: 'Evaluate impact of comorbidities and concurrent medications on cholesterol management'
  - Add instruction in prompt: 'Assess social determinants of health affecting medication adherence (cost, access, education, support system)'
  - Add instruction in prompt: 'Consider cardiovascular risk factors and overall treatment goals in context of medication adherence'
  - Modify section in prompt: 'Expand data correlation requirements to include BMI trends, blood pressure patterns, and diabetes markers if present'
- **Expected Impact**: Enhanced analysis will provide a more complete picture of factors affecting medication adherence and treatment effectiveness, leading to more actionable insights for improving patient outcomes

#### Health Query Response/Analysis
<details>
<summary>View the agent's full medical approach</summary>

```
Detailed medical approach including:

**What specialists are needed and why:**
1. **Cardiologist/Lipidologist** - Primary specialist needed for comprehensive lipid management analysis, medication optimization, and cardiovascular risk assessment
2. **Clinical Pharmacist** - To analyze medication adherence patterns, dosing changes, and potential drug interactions
3. **Endocrinologist** - May be needed given the metabolic nature of dyslipidemia and potential underlying metabolic conditions

**Key data points to investigate:**
1. **Medication Timeline Analysis:**
   - Multiple medication changes noted (rosuvastatin doses: 5mg, 10mg, 20mg; ezetimibe 10mg added)
   - Need to correlate medication changes with lab results
   - Gaps in medication records suggest potential adherence issues

2. **Lab Result Trends:**
   - LDL cholesterol: Improved from 122 mg/dL (Sept 2021) to 85 mg/dL (April 2025)
   - HDL cholesterol: Persistently low (33-47 mg/dL), often below target
   - Triglycerides: Variable, ranging from 51-426 mg/dL
   - Recent worsening: April 2025 shows deterioration in lipid profile

3. **Medication Adherence Patterns:**
   - Gaps between medication prescriptions (e.g., no records between Oct 2024 and April 2024)
   - Combination therapy started (rosuvastatin + ezetimibe) but timing unclear

**Potential correlations to explore:**
1. **Statin intensity changes vs. LDL response**
2. **Addition of ezetimibe timing vs. lipid improvements**
3. **Medication gaps vs. lipid profile deterioration**
4. **Seasonal or temporal patterns in adherence**
5. **Provider changes and their impact on medication continuity**

**Immediate concerns noted:**
1. **Recent lipid profile deterioration** (April 2025): 
   - LDL increased to 85 mg/dL
   - HDL decreased to 33 mg/dL (below normal)
   - Triglycerides elevated to 153 mg/dL

2. **Medication adherence gaps** suggesting potential non-compliance

3. **Persistently low HDL** throughout the monitoring period

4. **Historical very high triglycerides** (up to 426 mg/dL) indicating possible metabolic syndrome or genetic lipid disorder

This requires a comprehensive analysis of medication adherence patterns, temporal correlations with lab results, and assessment of treatment effectiveness over the 10+ year period of available data.
```
</details>


### Test Case: complex_002 ❌

**Health Query:**  
How has my HbA1c level changed since I started taking metformin, has my dosage been adjusted over time based on my lab results, and is there a correlation between these changes and my weight measurements during the same period?

**Response Time:** 70.1s

#### Evaluation Summary

| Dimension | Expected | Actual | Score | Target | Status |
|-----------|----------|--------|-------|--------|--------|
| **Complexity Classification** | COMPLEX | COMPLEX | 1.00 | 0.90 | ✅ PASS |
| **Specialist Selection** | endocrinology, nutrition, pharmacy | data_analysis, endocrinology, laboratory_medicine, nutrition, pharmacy | 0.90 | 0.85 | ✅ PASS |
| **Analysis Quality** | ≥0.80 | 0.75 | 0.75 | 0.80 | ❌ FAIL |
| **Tool Usage** | Effective | 1 calls | 1.00 | 0.90 | ✅ PASS |
| **Response Structure** | Valid XML | Valid | 1.00 | 0.95 | ✅ PASS |

#### 🔬 LLM Judge Failure Analysis

**Analysis Quality Issue:**
- **Problem**: The analysis lacks comprehensive evaluation of several critical aspects of diabetes management and fails to address important clinical correlations beyond basic metrics
- **Root Cause**: The CMO's analysis focused primarily on direct data points but missed analyzing broader clinical implications, treatment guidelines compliance, and metabolic health indicators
- **Priority**: HIGH
- **Weak Components**:
  - Comprehensive Approach: Failed to address lifestyle factors, medication side effects, kidney function monitoring, cardiovascular risk assessment, and dietary/exercise impacts on treatment efficacy
- **Prompt to Update**: `backend/services/agents/cmo/prompts/1_initial_analysis.txt`
- **Recommended Prompt Changes**:
  - Add instruction in prompt: 'Evaluate broader metabolic health indicators including lipid profiles, blood pressure trends, and kidney function in relation to metformin therapy'
  - Add instruction in prompt: 'Assess lifestyle modifications, diet patterns, and physical activity levels that could impact treatment effectiveness'
  - Add instruction in prompt: 'Review cardiovascular risk factors and their relationship to diabetes management'
  - Modify section in prompt: 'Include analysis of potential medication side effects, tolerability, and impact on patient adherence'
  - Add instruction in prompt: 'Compare current treatment approach against latest diabetes management guidelines and standards of care'
- **Expected Impact**: Enhanced analysis will provide a more holistic view of diabetes management, considering multiple health domains and treatment factors that influence glycemic control and overall patient outcomes

#### Health Query Response/Analysis
<details>
<summary>View the agent's full medical approach</summary>

```
Detailed medical approach including:

**What specialists are needed and why:**
1. **Endocrinologist** - Primary specialist needed to analyze HbA1c trends, diabetes management effectiveness, and medication adjustments
2. **Primary Care Physician** - To evaluate overall metabolic health and weight management in context of diabetes treatment
3. **Clinical Pharmacist** - To assess metformin dosing strategy and potential for optimization based on glycemic control

**Key data points to investigate:**
1. **HbA1c trajectory**: Limited data shows only 4 HbA1c values (5.7% to 6.1%) over 5+ years, which is insufficient for proper trend analysis
2. **Metformin dosing consistency**: Patient has been on consistent 500 MG dose throughout the entire treatment period (2021-2025) with no adjustments
3. **Weight fluctuation patterns**: Significant weight changes observed - from ~235 lbs (2013-2014) down to ~192-205 lbs (2022-2024), then recent increase to 226.62 lbs (April 2025)
4. **Timeline gaps**: Need to identify when metformin was actually initiated (first record shows September 2021)

**Potential correlations to explore:**
1. **Weight-HbA1c relationship**: Initial weight loss appears to correlate with good glycemic control (HbA1c 5.7-5.9%), but recent weight gain (226.62 lbs) may relate to slight HbA1c increase (6.1%)
2. **Medication adherence impact**: Consistent metformin records suggest good adherence, but need to verify frequency/timing
3. **Time-based patterns**: Need more frequent HbA1c monitoring to establish clear cause-effect relationships

**Immediate concerns noted:**
1. **Insufficient HbA1c monitoring**: Only 4 values over 5 years is below standard diabetes care (should be 2-4 times yearly)
2. **Recent weight gain**: 26.66 lb increase from early 2024 to April 2025 requires investigation
3. **No dose adjustments**: Despite weight changes and time on therapy, metformin dose remained static at 500 MG
4. **Missing baseline data**: No HbA1c values from before metformin initiation to establish true treatment effect

This analysis requires comprehensive investigation including gathering additional historical data, evaluating monitoring frequency, and assessing the need for treatment optimization.
```
</details>


## Visualizations

### Performance by Dimension
The chart below shows how the CMO Agent performs across each evaluation dimension compared to target thresholds:

![Dimension Scores](./dimension_scores.png)

### Additional Performance Charts

Click on any chart below to view additional performance insights:

| Chart | What It Shows | Key Insights |
|-------|---------------|--------------|
| **[Complexity Performance](./complexity_performance.png)** | Metrics by query complexity (STANDARD vs COMPLEX) | See if certain query types perform better |
| **[Response Time Distribution](./response_time_distribution.png)** | Histogram of processing times | Understand performance consistency |
| **[Specialty Heatmap](./specialty_heatmap.png)** | Which specialists are selected together | Identify common specialist combinations |